Researchers Discover Gene Variant That Delays Alzheimer's Onset

Study of Colombian family reveals protective effects of APOE3 Christchurch variant, offering new hope for treatment development.

The APOE3 Christchurch variant delays Alzheimer's symptoms by approximately five years in high-risk individuals.
Researchers studied over 1,000 family members, identifying 27 with the protective gene variant.
The findings suggest potential for developing drugs that mimic the gene's effects.
Previous focus on a single patient is now supported by broader family data.
Further studies are needed to confirm the gene's protective impact across diverse populations.